A147 COMBINING INFLIXIMAB TROUGH LEVELS AND FECAL CALPROTECTIN LEVELS WITH CLINICAL DATA HAS THE POTENTIAL TO GUIDE CLINICAL DECISION-MAKING IN IMPROVING OUTCOMES FOR INFLAMMATORY BOWEL DISEASE PATIENTS ON MAINTENANCE INFLIXIMAB.

BACKGROUND: Infliximab (IFX) induces and maintains remission in Crohn’s Disease (CD) and Ulcerative Colitis (UC). Secondary loss of response occurs in up to 45% of CD and 60% of UC patients on maintenance IFX. Studies are inconclusive on ideal IFX trough levels (ITLs) to prevent loss of response; re...

詳細記述

保存先:
書誌詳細
出版年:J Can Assoc Gastroenterol
主要な著者: Amin, A, Prosser, C, Kroeker, K I, Wang, H, Shalapay, C, Dhami, N, Fedorak, D K, Halloran, B P, Dieleman, L A, Goodman, K, Fedorak, R, Huang, V
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2018
主題:
Poster Presentations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6507628/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy008.148
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料